Sangamo Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
12/11/2024 23:16
* Sangamo Therapeutics Inc SGMO.OQ reported quarterly
adjusted
earnings of 4 cents per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of -59 cents. The mean expectation of
eight analysts for the quarter was for a loss of 3 cents per
share. Wall Street expected results to range from -14 cents
to 16 cents per share.
* Revenue rose 425.8% to $49.41 million from a year ago;
analysts
expected $17.94 million.
* Sangamo Therapeutics Inc's reported EPS for the quarter
was 4
cents.
* The company reported quarterly net income of $9.39
million.
* Sangamo Therapeutics Inc shares had risen by 211.7% this
quarter and gained 397.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 22.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Sangamo
Therapeutics Inc is $3.00
This summary was machine generated from LSEG data November 12 at
11:16 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.03 0.04 Beat
Jun. 30 2024 -0.15 -0.18 Missed
Mar. 31 2024 -0.21 -0.27 Missed
Dec. 31 2023 -0.26 -0.34 Missed